Results 71 to 80 of about 158,916 (259)
High‐Altitude Hypoxemia in Adults With Sickle Cell Disease (SCD)
American Journal of Hematology, EarlyView.
Mofiyin A. Obadina +4 more
wiley +1 more source
Prenatal Diagnosis, EarlyView.ABSTRACT In utero interventions are transformative in addressing genetic and anatomic conditions during fetal development. Next generation sequencing enables early genetic testing, playing a pivotal role in prenatal decision‐making by supporting risk stratification, precise and timely diagnosis, which directly informs eligibility for fetal surgical and
Matthew A. Shear +7 more
wiley +1 more source
PB2240: SILENT GLOBIN MUTATIONS. 10 YEARS REFERRALS FOR GENETIC COUNSELING.
HemaSphere, 2022 S. Theodoridou +7 more
doaj +1 more source
, 1993 Monthly newsletter providing updates of interest to the Boston University School of Medicine ...
Boston University School of Medicine Office of Informational Services
core
Diagnosed After Birth—But Detectable Before? A Cohort Study of Prenatal Testing Potential
Prenatal Diagnosis, EarlyView.ABSTRACT Objective To evaluate the yield of prenatal genetic testing in infants with a confirmed genetic diagnosis. Methods We retrospectively reviewed records of infants with a genetic diagnosis who were evaluated using a standardized genetic consult and testing approach. The predicted yield of various prenatal genetic sceening and diagnostic tools in
Allison Schartman +6 more
wiley +1 more source
PAIN MANAGEMENT IN PATIENTS WITH SICKLE CELL DISEASE – A REVIEW [PDF]
European Medical Journal Hematology, 2013 Pain is defined, by the International Association for the Study of Pain (IASP), as an ‘unpleasant sensitive and emotional experience, associated with or described in terms of tissue lesion’.
Sophia Delicou, Konstantinos Maragkos
doaj
Study of Pregnancy Outcome in E-Beta Thalassaemia Mothers [PDF]
, 2009 Forty eight E-Beta thalassaemia patients were studied in NRS Medical College, Kolkata, West Bengal during the period from 2000-2006. In all patients Hb% ranged from 5.2g% - 9.6g%.
Bhattacharyaya, Maitryaee +1 more
core +1 more source
Randomized phase 2 trial of regadenoson for treatment of acute vaso-occlusive crises in sickle cell disease [PDF]
, 2017 Key Points Regadenoson did not reduce iNKT cell activation to a prespecified level when administered to patients with SCD. Because iNKT cell activation was not reduced, the benefit of iNKT cell-based therapies in SCD cannot be determined.
Achebe, Maureen +14 more
core +2 more sources
Prenatal Diagnosis, EarlyView.ABSTRACT Sickle cell disease (SCD) affects millions worldwide but has limited treatment options, most of which carry significant side effects. At present, the only curative treatment for SCD is allogeneic or gene‐modified autologous hematopoietic stem cell (HSC) transplantation (Tx).
Oluwaseun O. Babatunde +4 more
wiley +1 more source